Potent corticotropin-releasing factor (CRF) receptor antagonist (Ki
values are 2, 1.5 and 1 nM at CRF1
). Reduces ACTH secretion, blocks delayed gastric emptying and is neuroprotective in vivo
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold with the permission of the SALK Institute
Potent, structurally constrained agonists and competitive antagonists of corticotropin-releasing factor.
Gulyas et al.
Peripheral injection of a new corticotropin-releasing factor (CRF) antagonist, astressin, blocks peripheral CRF- and abdominal surgery-induced delayed gastric emptying in rats.
Martinez et al.
Astressin, a novel and potent CRF antagonist, is neuroprotective in the hippocampus when administered after a seizure.
Maecker et al.
Brain Res., 1997;744:166
Corticotropin releasing factor receptors and their ligand family.
Perrin and Vale